Rahimi: Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial [N-acetylcysteine]

Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial

Rahimi et al., Jundishapur Journal of Natural Pharmaceutical Products, doi:10.5812/jjnpp-129817

Rahimi et al., Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial, Jundishapur Journal of Natural Pharmaceutical Products, doi:10.5812/jjnpp-129817

Oct 2022 Source PDF

Twitter
Facebook

All Studies Meta

RCT 40 ICU patients in Iran, showing lower mortality with NAC treatment, without statistical significance. Single dose intravenous NAC 300 mg/kg.

Important missing comments or errors? Let us know.

risk of death, 33.3% lower, RR 0.67, p = 0.19, treatment 10 of 20 (50.0%), control 15 of 20 (75.0%), NNT 4.0.

hospitalization time, 7.5% lower, relative time 0.92, p = 0.63, treatment 20, control 20.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Rahimi et al., 8 Oct 2022, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 10 authors.

All Studies All Outcomes Submit Updates or Corrections

This Paper N-acetylcys..All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit